Companies ›Consumer Cyclicals ›GWIN.PK

GWIN.PK — OTC Casinos & Gaming

Reska Biotech Inc

$0,51

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

61,6 %

ROE

17,8 %

Net margin

50,5 %

Debt / equity

0,00

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Reska Biotech Inc operates in the Casinos & Gaming industry, providing services and products related to the gaming sector.

Business. Reska Biotech Inc operates in the Casinos & Gaming industry within the Cyclical Consumer Services sector. The company is listed on the OTC market under the ticker symbol GWIN.PK. Specific details regarding its operating segments, headquarters location, and geographic presence are not available in the provided data.

Classification92 %

SectorConsumer Cyclicals

Business sectorCyclical Consumer Services

IndustryCasinos & Gaming

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

17,8 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning GWIN.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary · THIS SECTOR+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to GWIN.PK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Reska Biotech Inc operates in the Casinos & Gaming industry within the Cyclical Consumer Services sector. The company is listed on the OTC market under the ticker symbol GWIN.PK. Specific details regarding its operating segments, headquarters location, and geographic presence are not available in the provided data.

Classification92 %

SectorConsumer Cyclicals

Business sectorCyclical Consumer Services

IndustryCasinos & Gaming

AI synthesis

GENERATED

Reska Biotech Inc maintains a strong liquidity position with a current ratio of 0.86, indicating that its current liabilities slightly exceed its current assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a debt-free capital structure. The company's operating cash flow of $2,325,190 supports its liquidity, although its cash and equivalents are relatively low at $13,540.

In terms of profitability, Reska Biotech Inc demonstrates a return on equity of 17.76%, which is a strong indicator of efficient use of shareholders' equity to generate profits. The company's operating income of $1,085,600 and net income of $889,400 suggest a healthy margin, although specific comparisons to industry medians are not available in the provided data.

The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company's exposure is not detailed, but the absence of segmental or geographic diversification may pose concentration risks.

Reska Biotech Inc's growth trajectory is not explicitly outlined in the available data, but the company's operating cash flow and net income suggest a stable financial performance. The absence of capital expenditures indicates that the company is not currently investing in new projects or expansions.

The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The absence of long-term debt and the presence of positive operating cash flow contribute to a low liquidity risk profile. The company's dilution risk is also low, as there are no signs of imminent share issuance or dilution pressures.

Recent events and filings do not show any significant developments for Reska Biotech Inc. The company's financial statements and risk assessment do not indicate any material changes or events that would impact its operations or financial position in the near term.

Key takeaways

Reska Biotech Inc has a strong return on equity of 17.76%, indicating efficient use of shareholders' equity.
The company is debt-free, with a debt-to-equity ratio of 0.0, which reduces financial risk.
Reska Biotech Inc has a low liquidity risk profile, supported by positive operating cash flow and no long-term debt.
The company's financial performance is stable, with no immediate signs of dilution or liquidity pressures.
The absence of segmental and geographic diversification may pose concentration risks.

Bull / Bear case

Generated · model-assisted

BULL CASE · 1

The company maintains a zero debt-to-equity ratio, avoiding leverage risks present in peers.

BEAR CASE · 2

Net income declined to a loss of $2.07 million in the latest fiscal period.

Free cash flow remained negative at -$2.07 million, showing continued cash burn.

In focus — financials by report

Valuation FY

Market price

$0,51

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

$13.5k

Current ratioⓘ

0.9

Debt / equityⓘ

0.0

ROAⓘ

—

ROEⓘ

17.8%

Cash conversionⓘ

261.0%

CapEx / revenueⓘ

-1.8%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin61,7 %Best in class

Net Margin50,5 %Best in class

ROE17,8 %Above median

Capex / Rev-1,8 %Above median

D/E0,00Above median

Cash Conv2,61Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Reska Biotech Inc Market data — financials · 2026-05-28

Ownership & reference

Insider activity

— missing data

Short positioning

19shares short0.0% vs prior

1days to cover

408fails-to-deliver

as of 2026-06-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

GWIN.PKCanonical

OTC · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread